Drug intelligence / Profile preview

lappaconitine

Development stage
Unknown
Lead developer
Shanghai Institute of Materia Medica
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Injectable, Transdermal
01

Overview

Lappaconitine is a natural diterpene alkaloid originally isolated from Aconitum sinomontanum (sacred tower giant Chinese monkshood), a plant used in traditional Chinese medicine. It acts primarily as a voltage-gated sodium channel blocker, distinguishing it from other aconitum alkaloids like aconitine, which are sodium channel activators[1][2][6]. Lappaconitine exhibits multiple pharmacological activities including analgesic, anti-inflammatory, antiarrhythmic (class IC), antiepileptic/anticonvulsant, and antitumor effects[2][3][7]. Its analgesic effect is non-opioid in nature and has been shown to be effective for moderate to severe pain management such as cancer pain and postoperative pain[3][6]. The compound also downregulates P2X3 receptor expression in dorsal root ganglion neurons and modulates inflammatory cytokines via the NF-kB and MAPK pathways[2][3]. Clinically, lappaconitine or its hydrobromide salt has been used mainly in China for arrhythmias and as an analgesic agent; however, its development for arrhythmia was discontinued after phase II trials due to efficacy or safety concerns[4].

Brand names
allapinine
Other names
lappaconitine hydrobromideLAQG3030QG-3030QG 3030
02

Targets

SCN10A (Sodium channel protein type X alpha subunit)SCN11A (NaV1.9)SCN9A (Sodium channel protein type 9 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)P2X3 (P2X purinoceptor 3)

Beyond the preview

Go deeper on lappaconitine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lappaconitine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call